welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Avidity Biosciences Receives Investment from CureDuchenne
Avidity Biosciences, a privately held biotech company pioneering a new class of precision medicines based upon antibody-oligonucleotide conjugates, announced today that CureDuchenne has made an equity investment in the company. Funding will help to advance pre-clinical development of potential therapies to treat patients with Duchenne muscular dystrophy (DMD).
rareRelated
-
Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Mu...Sarepta Therapeutics, Inc., the leader i...
-
Development of CRISPR-Mediated Systems in the Study of Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a s...
-
Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene TherapyPfizer Inc. announced that its investiga...
-
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin geneThis guidance is not intended to affect ...
-
UCLA research could be first step toward healing the hearts of children with DuchenneAfter a progressive weakening of the mus...
-
Catabasis Quarterly: Updates on edasalonexent and clinical trialsWe are pleased to announce that we have ...
-
Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients With Duchenne Muscular Dystr...Capricor Therapeutics, Inc., a biotechno...
